Blog - Page 4089 of 5479

FridayDec 19, 2008 10:02 am

HST Global, Inc. (HSTC.OB) Strengthens Scientific Board with New Member

HST Global, Inc. announced earlier this month that Dr. Kyl Smith has joined its Scientific Board. Much of Dr. Smith’s visibility has been earned in the world of natural medicine. He is a noted researcher, inventor, lecturer, author and scientist, and is known as the inventor of Focus Factor®, the number-one selling brain support product in North America for the last seven years. Dr. Kyl's passion is teaching doctors how to use nutritional therapies to improve cognitive function. He has been featured on numerous radio and television programs across the country, is the author of the acclaimed Brighter Mind® book…

FridayDec 19, 2008 8:55 am

MAP Pharmaceuticals Inc. (MAPP) Announces Deal with AstraZeneca, $800 Million + Potential

Looking at the wide variety of companies working to make a go of their business makes one wonder when and if any of them will actually make the leap from development to profitable. So many companies struggle through the year, with only a hope of breaking through. Every once in a while, however, a company makes the leap after laying out millions to get their product to market. Being willing to take the risk and invest is where the savvy investor profits. The risk remains, but it can certainly result in a nice profit. MAP Pharmaceuticals Inc., a development stage…

FridayDec 19, 2008 8:26 am

Hybrid Technologies, Inc. (HYBR.OB) Expands R&D Efforts, Increases Capabilities

Earlier this year in May, Hybrid Technologies, Inc. opened a fully-owned subsidiary in India with the purpose of creating greater in-house capabilities for research and development (R&D) as well as utilize the vast knowledge pool of India’s engineers. Hybrid Technologies, incorporated in Nevada in 2000, is a development-stage technology company that continues to focus its resources and efforts on the development and marketing of lithium-powered vehicles and products used in commercial and residential properties. The company is focused on developing scooters, bicycles, mopeds, motorcycles, cars and battery backup for home power systems, hoping to convert all to zero-emission, lithium-powered vehicles…

FridayDec 19, 2008 7:46 am

Exchange Media Corp. (EXMD.PK): The Mobile Multimedia Revolution

On his way into the city, a student catches segments of his favorite television show; an entrepreneur checks where his stocks are trading while walking to the office; and a mother takes photos of her little boys playing in the park – all on a mobile phone. The mobile multimedia revolution is taking the world by storm, regardless of age, citizenship gender or class. As wireless markets continue to evolve, handsets are becoming the nexus of mobile content and applications in developing countries around the world. Growth in the mobile multimedia space shows a strong demand for mobile data content…

FridayDec 19, 2008 7:08 am

BWI Holdings, Inc. Announces Second Quarter Results

BWI Holdings, Inc. (OTCBB: BWIH), operating as Budget Waste Inc. (the "Company"), is pleased to announce its financial results for the quarter ended October 31, 2008. Selected financial results are as follows: See table at http://www.budgetwaste.com/Press%20Releases/12192008.html Mr. Jim Can, the Company's CEO, states: "We are very pleased with the progress we have made in regards to controlling our costs and processes. We are finally able to reap the benefits of combining excellent customer service with reasonable margins in a very tough economic climate. We will continue to add process improvements and strive to maintain a positive bottom line." Unfortunately due…

FridayDec 19, 2008 6:01 am

Kraig Biocraft Laboratories, Inc. (KBLB.OB) Makes Significant Breakthrough in the Labs

Earlier this month, Kraig Biocraft Laboratories announced that its scientific team, including Dr. Malcolm Fraser, Dr. Wang, Dr. Sohn, and other members, have found a process capable of doubling the number of gene transfers performed, greatly increasing productivity of the spider silk and high performance polymer development program. Kraig Biocraft is focused on developing and commercializing high performance polymers using spider silk gene sequences. The company intends to participate in the $92 billion market for high performance and technical fibers. Last year, Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame and…

FridayDec 19, 2008 5:51 am

What Employment Says About the Economy

Increasingly Complex Conditions Call for Closer Look at Jobs Data During the first half of 2008, as the national unemployment rate stayed fairly steady, economists focused on a lesser-known aspect of the employment situation: people out of work for more than six months. The number of people in this situation grew at the fastest rate (on a year-over-year basis) since February 2003. Although the percentage of long-term unemployed has been much higher and much more serious in the past, the growth rate was sharp enough to attract attention. It’s a reminder that as important as the national unemployment rate is,…

ThursdayDec 18, 2008 11:31 am

StemCells, Inc. (STEM) Announces FDA Approval to Initiate Clinical Trial of HuCNS-SC(R) Cells in a Myelin Disease

StemCells, Inc. announced this morning that it has received approval from the FDA to begin a clinical trial of the Company's proprietary HuCNS-SC product candidate (purified human neural stem cells) to treat Pelizaeus-Merzbacher Disease (PMD), a fatal brain disorder that primarily affects young children. As of today, there are no approved treatments for this disease. According to the press release, this is the Company's second FDA-approved clinical trial to evaluate HuCNS-SC cells as a potential treatment for neurodegenerative diseases. The first study to be approved was the Company's Phase I clinical trial of HuCNS-SC cells to treat neuronal ceroid lipofuscinoses…

ThursdayDec 18, 2008 11:24 am

BioSpecifics Technologies Corp. (BSTC.OB) Partners with Pfizer and Auxilium for XIAFLEX(TM) in Europe

Today, BioSpecifics Technologies announced that its partner Auxilium Pharmaceuticals, Inc. has signed a license agreement with Pfizer, Inc. to market XIAFLEX in Europe and other territories for the treatment of Dupuytren's disease and Peyronie's disease. As terms of the partnership, BioSpecifics will receive $6.375 million of the $75 million upfront payment paid to Auxilium by Pfizer, and will be entitled to 8.5% of the $410 million in additional milestone payments that may be made by Pfizer to Auxilium in the future. Thomas L. Wegman, President of BioSpecifics, stated, “We are pleased that Pfizer, the world's largest pharmaceutical company, has committed…

ThursdayDec 18, 2008 10:34 am

HST Global, Inc. (HSTC.OB) is “One to Watch”

HST Global, Inc. is a development-stage biotechnology company committed to acquiring, developing and commercializing innovative products to enhance cancer care. The company determines to acquire proprietary rights to these products, fund their R&D, and bring the products to market. Since HST’s inception, they have focused their efforts and resources primarily on Salicinium, a clinical stage drug candidate, as well as raising capital and recruiting personnel. The company’s focus is on in-licensing and further advancing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer. Although the cost of licensing drug candidates that have…

Site Search

Company Search